基因組編輯市場規模、佔有率和成長分析（按技術、交付方式、應用、改進和地區分類）—產業預測（2026-2033 年）

全球基因組編輯市場預計到 2024 年將達到 89.9 億美元，到 2025 年將達到 105 億美元，到 2033 年將達到 363.7 億美元，在預測期（2026-2033 年）內複合年成長率為 16.8%。

全球基因組編輯市場正經歷強勁成長，這主要得益於成功的臨床前模型、日益激烈的競爭、基因編輯技術的進步以及農業生物技術的日益普及。基於CRISPR的工具的快速發展顯著拓展了該行業在疾病檢測和治療創新方面的視野，為服務供應商在尚未開發的市場中提供了盈利機會。政府投入的增加和基因組學相關舉措的激增進一步推動了市場擴張，各公司正透過許可協議和策略合作擴大其市場佔有率。人工智慧的整合正在革新產業結構，透過最佳化CRISPR設計、加速標靶發現和最大限度地減少脫靶效應，最終提高基因修飾的精準度，並簡化罕見疾病和腫瘤細胞及基因治療的工作流程。

全球基因組編輯市場按技術、遞送方式、應用、應用類型和地區進行細分。依技術分類，可分為 CRISPR/Cas9、TALEN/megaTAL、ZFN 和Meganucleases。依遞送方式分類，可分為體外和體內。依應用分類，可分為基因工程和臨床應用。按應用類型分類，可細分為合約開發和自主研發。按地區分類，分析涵蓋北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球基因組編輯市場促進因素

隨著各國政府和私人投資者投入大量資源研發創新基因組編輯技術，以期攻克罕見疾病、癌症和遺傳異常等難題，全球基因組編輯市場正經歷顯著成長。由美國國立衛生研究院 (NIH)主導的體細胞基因組編輯舉措(SCGEI) 等項目，以及創投對 CRISPR相關企業的創業投資投入，都在加速該領域的發展。資金的湧入使得製藥公司、生技公司和學術機構能夠快速開發先進的基因編輯工具和治療平台，為基因醫學領域的潛在突破創造了蓬勃發展的環境。

限制全球基因組編輯市場的因素

全球基因組編輯市場面臨許多挑戰，主要源自於圍繞人類基因組編輯（尤其是生殖細胞系編輯）的複雜倫理考量。各地政府對CRISPR技術應用的不同監管規定阻礙了其商業化進程。諸如基因編輯嬰兒爭議等備受矚目的事件，進一步加劇了公眾的認知困境。因此，這些倫理困境，加上嚴格的法律體制和公眾的不信任，導致基因組編輯技術在農業和醫療保健領域的接受度和核准緩慢。

全球基因組編輯市場趨勢

在全球基因組編輯市場，開發能夠提高精準度並最大限度減少脫靶效應的先進編輯技術已成為顯著趨勢。鹼基編輯、先導編輯器以及包括Cas12和Cas13在內的CRISPR變體等創新技術，正引領更安全、更有效的基因修飾方法。這些最尖端科技無需雙鏈即可實現逐個鹼基的編輯，標誌著基因治療方法的一個突破性轉折點。尤其值得一提的是，該領域的主要企業正日益專注於先進的可程式設計編輯儀器，這表明他們更加重視客製化解決方案，而這些方案有望徹底改變治療應用和基因研究。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球基因組編輯市場規模（依技術及複合年成長率分類）（2026-2033 年）

• （CRISPR）/Cas9
• TALENs／MegaTALs
• ZFN
• Meganucleases

全球基因組編輯市場規模（按交付方式和複合年成長率分類）（2026-2033 年）

• 體外
• 體內

全球基因組編輯市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 基因工程
• 臨床應用

全球基因組編輯市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 合約類型
• 內部開發類型

全球基因組編輯市場規模（按地區分類）及複合年成長率（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• CRISPR Therapeutics AG
• Editas Medicine, Inc.
• Danaher Corporation
• Intellia Therapeutics, Inc.
• Sangamo Therapeutics, Inc.
• Beam Therapeutics Inc.
• Prime Medicine, Inc.
• Thermo Fisher Scientific, Inc.
• Horizon Discovery Group plc
• Synthego Corporation
• Caribou Biosciences, Inc.
• Precision BioSciences, Inc.
• Locus Biosciences, Inc.
• ToolGen, Inc.

結論與建議

Global Genome Editing Market size was valued at USD 8.99 Billion in 2024 and is poised to grow from USD 10.5 Billion in 2025 to USD 36.37 Billion by 2033, growing at a CAGR of 16.8% during the forecast period (2026-2033).

The global genome editing market is experiencing robust growth driven by successful preclinical models, heightened competition, and advancements in gene editing technologies, alongside increasing adoption of agricultural biotechnology. The rapid evolution of CRISPR-based tools has significantly broadened industry horizons for disease detection and treatment innovation, presenting lucrative opportunities for service providers in untapped markets. Rising government funding and a surge in genomics initiatives are further propelling market expansion, as companies engage in licensing agreements and strategic partnerships to enhance their presence. The integration of artificial intelligence is revolutionizing the landscape by optimizing CRISPR design, accelerating target discovery, and minimizing off-target effects, ultimately improving precision in gene modifications and streamlining workflows in cell and gene therapies for rare diseases and oncology applications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Genome Editing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Genome Editing Market Segments Analysis

The global genome editing market is segmented into technology, delivery mode, application, mode, and region. By technology, the market is classified into (CRISPR)/Cas9, TALENs/megaTALs, ZFN, and meganucleases. Depending on delivery mode, it is divided into ex-vivo and in-vivo. According to the application, the market is bifurcated into genetic engineering and clinical applications. As per mode, it is fragmented into contract and in-house. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Driver of the Global Genome Editing Market

The Global Genome Editing market is experiencing substantial growth as both governments and private investors channel considerable resources into innovative genome editing technologies aimed at addressing rare diseases, cancer, and genetic abnormalities. Programs such as the Somatic Cell Genome Editing initiative spearheaded by the U.S. National Institutes of Health, along with significant venture capital investments in CRISPR-related companies, are accelerating progress in this field. This influx of funding is enabling pharmaceutical firms, biotechnology companies, and academic institutions to rapidly develop advanced gene-editing tools and therapeutic platforms, fostering a dynamic environment ripe for breakthroughs in genetic medicine.

Restraints in the Global Genome Editing Market

The Global Genome Editing market faces significant challenges primarily due to complex ethical considerations surrounding human genome editing, especially with germline modifications. The commercialization process encounters obstacles due to the varying regulations imposed by regional authorities regarding the use of CRISPR technology. High-profile controversies, such as those related to gene-edited babies, further complicate public perception. As a result, these ethical dilemmas, combined with stringent legislative frameworks and a general sense of mistrust among the public, are contributing to a slowdown in the acceptance and approval of genome editing technologies within both agricultural and healthcare sectors.

Market Trends of the Global Genome Editing Market

The global genome editing market is witnessing a significant trend towards the development of advanced editing technologies that enhance precision and minimize off-target effects. Innovations such as base editors, prime editors, and variations of CRISPR, including Cas12 and Cas13, are paving the way for safer and more effective gene modifications. These state-of-the-art techniques allow for single-base edits without the need for double-strand breaks, marking a pivotal shift in gene therapy approaches. Notably, leading companies in the sector are increasingly focusing on sophisticated, programmable editing devices, indicating a growing emphasis on tailored solutions that promise to revolutionize therapeutic applications and genetic research.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Genome Editing Market Size by Technology & CAGR (2026-2033)

• Market Overview
• (CRISPR)/Cas9
• TALENs/MegaTALs
• ZFN
• Mega-nucleases

Global Genome Editing Market Size by Delivery Method & CAGR (2026-2033)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Genome Editing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Genetic Engineering
• Clinical Applications

Global Genome Editing Market Size by Mode & CAGR (2026-2033)

• Market Overview
• Contract
• In-House

Global Genome Editing Market Size & CAGR (2026-2033)

• North America (Technology, Delivery Method, Application, Mode)
  • US
  • Canada
• Europe (Technology, Delivery Method, Application, Mode)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Delivery Method, Application, Mode)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Delivery Method, Application, Mode)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Delivery Method, Application, Mode)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• CRISPR Therapeutics AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beam Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prime Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Discovery Group plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synthego Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caribou Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision BioSciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Locus Biosciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ToolGen, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations